ALC |
Absolute Lymphocyte Count |
APC |
Antigen-Presenting Cell |
ATP |
Adenosine Triphosphate |
BTLA |
B and T Lymphocyte Attenuator |
CALR |
Calreticulin |
CAR |
Chimeric Antigen Receptor |
CTLA4 |
Cytotoxic T-Lymphocyte-Associated Protein |
CRT |
Chemoradiotherapy |
DAMPs |
Damage-Associated Molecular Patterns |
DC |
Dendritic Cell |
HMGB1 |
High Mobility Group Box 1 |
HNSCC |
Head and Neck Squamous Cell Carcinoma |
HSP70/90 |
Heat Shock Proteins 70/90 |
ICD |
Immunogenic Cell Death |
ICI |
Immune Checkpoint Inhibitor |
irAEs |
Immune-related Adverse Events |
LA |
Locally Advanced |
LAG3 |
Lymphocyte Activation Gene 3 |
MDSC |
Myeloid-Derived Suppressor Cell |
MHC-1 |
Major Histocompatibility Complex class 1 |
NSCLC |
Non-Small Cell Lung Carcinoma |
OS |
Overall Survival |
PD-1 |
Programmed cell death 1 |
PD-L1 |
Programmed death-ligand 1 |
ROS |
Reactive Oxygen Species |
PFS |
Progression Free Survival |
RCC |
Renal Cell Carcinoma |
RT |
Radiation Therapy |
SBRT |
Stereotactic Body Radiation Therapy |
TGFβ |
Transforming Growth Factor Beta |
TIGIT |
T cell Immunoglobulin and ITIM domain |
TNFα |
Tumor Necrosis Factor Alpha |
Treg |
Regulatory T cells |
TREX1 |
Three prime Repair Exonuclease 1 |
TRAIL |
TNF-related Apoptosis-Inducing Ligand |
VISTA |
V-Domain Ig Suppressor of T cell Activation |